|Mr. Alexander Zwyer M.B.A.||Pres, CEO & Director||N/A||N/A||1969|
|Mr. Subhasis Roy M.B.A.||Interim Chief Financial Officer||N/A||N/A||1969|
|Dr. Silvia Panigone||Chief Operating Officer||N/A||N/A||1972|
|Mr. Eric Konofal M.D., Ph.D.||Chief Scientific Officer||N/A||N/A||1967|
|Dr. Christian C. Wenger Dr. iur., L.L.M., LL.M., Ph.D.||Gen. Counsel||N/A||N/A||1964|
|Ms. Sharon Keys||Head of Regulatory Affairs||N/A||N/A||N/A|
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.
NLS Pharmaceutics AG’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.